- Home
- MNDY vs MRNA Comparison
MNDY vs MRNA Comparison
Compare MNDY & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNDY
- MRNA
- Stock Information
- Founded
- MNDY 2012
- MRNA 2010
- Country
- MNDY Israel
- MRNA United States
- Employees
- MNDY N/A
- MRNA N/A
- Industry
- MNDY Computer Software: Prepackaged Software
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MNDY Technology
- MRNA Health Care
- Exchange
- MNDY Nasdaq
- MRNA Nasdaq
- Market Cap
- MNDY 9.5B
- MRNA 9.8B
- IPO Year
- MNDY 2021
- MRNA 2018
- Fundamental
- Price
- MNDY $195.94
- MRNA $24.70
- Analyst Decision
- MNDY Strong Buy
- MRNA Hold
- Analyst Count
- MNDY 21
- MRNA 15
- Target Price
- MNDY $298.19
- MRNA $37.15
- AVG Volume (30 Days)
- MNDY 1.0M
- MRNA 8.9M
- Earning Date
- MNDY 11-10-2025
- MRNA 11-06-2025
- Dividend Yield
- MNDY N/A
- MRNA N/A
- EPS Growth
- MNDY N/A
- MRNA N/A
- EPS
- MNDY 0.76
- MRNA N/A
- Revenue
- MNDY $1,100,240,000.00
- MRNA $3,078,000,000.00
- Revenue This Year
- MNDY $28.70
- MRNA N/A
- Revenue Next Year
- MNDY $22.30
- MRNA $11.12
- P/E Ratio
- MNDY $262.97
- MRNA N/A
- Revenue Growth
- MNDY 30.24
- MRNA N/A
- 52 Week Low
- MNDY $166.22
- MRNA $23.15
- 52 Week High
- MNDY $342.64
- MRNA $57.69
- Technical
- Relative Strength Index (RSI)
- MNDY 55.07
- MRNA 43.66
- Support Level
- MNDY $176.00
- MRNA $25.57
- Resistance Level
- MNDY $202.31
- MRNA $27.37
- Average True Range (ATR)
- MNDY 6.53
- MRNA 1.18
- MACD
- MNDY 2.25
- MRNA -0.22
- Stochastic Oscillator
- MNDY 85.52
- MRNA 7.25
About MNDY monday.com Ltd.
Monday.com is a work management platform allowing for increased collaboration and visibility across an organization. Delivered via a SaaS-based model, users can track progress across marketing and development initiatives, create and automate workflows, and manage IT approvals. Revenue is generated on a per-seat basis across several pricing tiers. As of fiscal 2024, the company had over 245,000 customers.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.